Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.74 |
| ▸ | CHKA | P35790 | 1/20 | 0.71 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.67 |
| ▸ | ACHE | P22303 | 1/20 | 0.66 |
| ▸ | PKM | P14618 | 1/20 | 0.66 |
| ▸ | MC4R | P32245 | 1/20 | 0.60 |
| ▸ | MC5R | P33032 | 1/20 | 0.60 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.55 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.55 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31010303 | 1.00 | KMT2A (0.74) | KMT2ACHKAHRH3ACHEPKM | |
| Hydrochloric Acid SCHEMBL16825143 | 0.98 | KMT2A (0.72) | KMT2ACHKAHRH3ACHEPKM | |
| SCHEMBL31097161 | 0.98 | KMT2A (0.77) | KMT2ACHKAHRH3ACHEPKM | |
| SCHEMBL31392631 | 0.94 | CHKA (0.79) | KMT2ACHKAHRH3ACHEPKM | |
| SCHEMBL27999347 | 0.90 | KMT2A (0.89) | KMT2ACHKAHRH3ACHEPKM | |
| SCHEMBL8852275 | 0.89 | CHKA (0.67) | KMT2ACHKAHRH3ACHEPKM | |
| SCHEMBL4750742 | 0.85 | KMT2A (1.00) | KMT2ACHKAACHEPKMMC4R | |
| SCHEMBL13940581 | 0.85 | CHKA (0.76) | KMT2ACHKAHRH3ACHEPKM | |
| SCHEMBL10135595 | 0.84 | SLC6A4 (0.64) | KMT2ACHKAHRH3ACHEPKM | |
| SCHEMBL6377576 | 0.84 | KMT2A (0.72) | KMT2ACHKAHRH3ACHEPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250186981-A1 | CATALYST COMPOSITION FOR CYCLIC OLEFIN POLYMERIZATION, AND METHOD FOR PREPARING CYCLIC OLEFIN-BASED OLIGOMER OR OLEFIN-BASED POLYMER BY USING SAME | KYUNGPOOK NATIONAL UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION (KR) | 2025-06-12 | — | — | US | disclosed |
| WO-2024043542-A1 | CATALYST COMPOSITION FOR CYCLIC OLEFIN POLYMERIZATION, AND METHOD FOR PREPARING CYCLIC OLEFIN-BASED OLIGOMER OR OLEFIN-BASED POLYMER BY USING SAME | 경북대학교 산학협력단 | 2024-02-29 | — | — | WO | disclosed |
| EP-3597649-B1 | COMPOSITIONS CONTAINING SUBSTITUTED [1,2,4]TRIAZOLO[1,5-A]PYRIMIDIN-7-YL COMPOUNDS AS PDE2 INHIBITORS | DART NEUROSCIENCE CAYMAN LTD (KY) | 2021-10-13 | — | — | EP | disclosed |
| EP-3536319-A1 | NOVEL COMPOUNDS THAT ARE ERK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2019-09-11 | — | — | EP | disclosed |
| EP-3134413-B1 | SUBSTITUTED [1,2,4]TRIAZOLO[1,5-A]PYRIMIDIN-7-YL COMPOUNDS AS PDE2 INHIBITORS | DART NEUROSCIENCE CAYMAN LTD (KY) | 2019-09-11 | — | — | EP | disclosed |
| US-20180093960-A1 | METHOD OF INHIBITING APOLIPOPROTEIN-E EXPRESSION WHILE INCREASING EXPRESSION OF AT LEAST ONE OF LDL-RECEPTOR PROTEIN OR ABCA1 PROTEIN COMPRISING ADMINISTERING A SMALL COMPOUND | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH | 2018-04-05 | — | — | US | disclosed |
| US-20180093960-A1 | METHOD OF INHIBITING APOLIPOPROTEIN-E EXPRESSION WHILE INCREASING EXPRESSION OF AT LEAST ONE OF LDL-RECEPTOR PROTEIN OR ABCA1 PROTEIN COMPRISING ADMINISTERING A SMALL COMPOUND | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH | 2018-04-05 | — | — | US | disclosed |
| EP-3083584-A1 | NITROGENOUS HETEROCYCLIC DERIVATIVES AND THEIR APPLICATION IN DRUGS | Sunshine Lake Pharma Co., Ltd. (CN) | 2016-10-26 | — | — | EP | disclosed |
| WO-2015090232-A1 | NITROGENOUS HETEROCYCLIC DERIVATIVES AND THEIR APPLICATION IN DRUGS | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2015-06-25 | — | — | WO | disclosed |
| EP-1737840-A1 | 1-AMINO-PHTHALAZINE DERIVATIVES, THE PREPARATION AND THE THERAPEUTIC USE THEREOF | Sanofi-Aventis (FR) | 2007-01-03 | — | — | EP | disclosed |
| WO-2005103033-A1 | 1-AMINO-PHTHALAZINE DERIVATIVES, THE PREPARATION AND THE THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2005-11-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180093960-A1 | METHOD OF INHIBITING APOLIPOPROTEIN-E EXPRESSION WHILE INCREASING EXPRESSION OF AT LEAST ONE OF LDL-RECEPTOR PROTEIN OR ABCA1 PROTEIN COMPRISING ADMINISTERING A SMALL COMPOUND | LDLR, APOB, NR1H2 | KMT2A 4002/4885CHKA 1648/4885HRH3 4475/4885 |
| US-20250186981-A1 | CATALYST COMPOSITION FOR CYCLIC OLEFIN POLYMERIZATION, AND METHOD FOR PREPARING CYCLIC OLEFIN-BASED OLIGOMER OR OLEFIN-BASED POLYMER BY USING SAME | PPOX, COG7, ODC1 | KMT2A 3802/4885CHKA 1126/4885HRH3 3813/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.